July 07, 2014

Minerva Neurosciences To Ring NASDAQ Stock Market Closing Bell On July 7, 2014

CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, MD, MBA, Minerva president and CEO, along with additional members of the senior leadership team, will ring the NASDAQ Stock Market Closing Bell this afternoon, July 7, 2014. The ceremony follows the announcement of the pricing of the company's initial public offering on June 30, 2014. Shares began trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014.

"The completion of our IPO was an important milestone in our company history and we are honored to commemorate this event and ring the closing bell at NASDAQ today," said Dr. Vivaldi.

A live webcast of the NASDAQ Closing Bell Ceremony (starting at 3:45 Eastern Time today, July 7) will be available at: https://new.livestream.com/nasdaq/live.

In March of this year, Minerva Neurosciences launched its new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Massachusetts. The establishment of a new corporate headquarters follows the appointment of Rogerio Vivaldi, MD, MBA, as the new president and CEO, and Marc Beer as the chairman of the board of directors of Minerva Neurosciences.

About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. 

Media contact:
Jen Ringler
Berry & Company Public Relations

Investor contact:
Renee Leck
Stern Investor Relations

SOURCE Minerva Neurosciences, Inc.

News Provided by Acquire Media